FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2570112540> ?p ?o ?g. }

• W2570112540 endingPage "3876" @default.
• W2570112540 startingPage "3876" @default.
• W2570112540 abstract "Abstract Abstract 3876 Poster Board III-812 Background Elotuzumab is a humanized monoclonal IgG1 antibody directed against CS1, a cell surface glycoprotein, which is highly and uniformly expressed in multiple myeloma (MM). In mouse xenograft models of MM, elotuzumab demonstrated significantly enhanced anti-tumor activity when combined with bortezomib compared to bortezomib alone (Van Rhee et al., Mol. Cancer Ther., in press, 2009). This phase 1/2 trial will determine the maximum tolerated dose (MTD), overall safety, pharmacokinetics (PK) and clinical response of elotuzumab in combination with bortezomib in patients with relapsed MM following 1-3 prior therapies. Methods The study consists of 4 escalating cohorts of elotuzumab (2.5 mg/kg to 20 mg/kg) administered on Days 1 and 11 and bortezomib (1.3 mg/m2) administered on Days 1, 4, 8 and 11 of a 21-day cycle. Patients with progressive disease at the end of Cycle 2 or 3 also receive oral dexamethasone (20 mg) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of each subsequent cycle. Patients with stable disease or better at the end of 4 cycles will continue treatment for 6 or more cycles unless withdrawn earlier due to unexpected toxicity or disease progression. Key entry criteria: age ≥ 18 years; confirmed diagnosis of MM and documentation of 1 to 3 prior therapies; measurable disease M-protein component in serum and/or in urine; and no prior bortezomib treatment within 2 weeks of first dose. Results To date, a total of 16 MM patients with a median age of 64 years have been enrolled in the study. The median time from initial diagnosis of MM was 3.5 years and patients had received a median of 2 prior MM treatments. Patients have been treated in four cohorts; 3 each in 2.5, 5 and 10 mg/kg elotuzumab cohorts, and 7 in the 20 mg/kg elotuzumab cohort. No dose limiting toxicity (DLT) was observed during the first cycle of the study and the MTD was not established. Five SAEs have been reported in four patients in later treatment cycles; two events, chest pain and gastroenteritis, occurring in one patient, were considered elotuzumab-related. Other SAEs include grade 3 sepsis, vomiting, pneumonia and grade 2 dehydration. The most common AEs reported include Grade 1-3 diarrhea, constipation, nausea, fatigue, thrombocytopenia, neutropenia, anemia and peripheral neuropathy. The best clinical response (EBMT criteria) for the 16 patients who have received at least two cycles of treatment is shown in the table below. Preliminary PK analysis suggests a serum half-life of 10-11 days at higher doses (10 and 20 mg/kg). Preliminary analysis of peripheral blood mononuclear cells and bone marrow of patients on study indicates that objective responses in the study correlate well with complete saturation of CS1 sites by elotuzumab on bone marrow plasma and NK cells. Conclusions The combination of elotuzumab with bortezomib has a manageable adverse event profile and shows promising preliminary efficacy with ≥PR in 44% and ≥MR in 75% of all enrolled patients. Accrual is ongoing in the expanded 20 mg/kg cohort. Updated safety, efficacy, and PK data will be presented at the meeting. Disclosures: Jakubowiak: Millennium: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Centocor Ortho Biotech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Exelixis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Off Label Use: Bortezomib in combination with elotuzumab for the treatment of relapsed/refractory multiple myeloma. Bensinger:Millennium: Membership on an entity's Board of Directors or advisory committees. Siegel:Millennium: Speakers Bureau; Celgene: Speakers Bureau. Zimmerman:Millennium: Speakers Bureau; Centecor: Speakers Bureau. Van Tornout:BMS: Employment. Zhao:Facet Biotech: Employment. Singhal:Facet Biotech: Employment. Anderson:Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Millennium: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding." @default.
• W2570112540 created "2017-01-13" @default.
• W2570112540 creator A5013047847 @default.
• W2570112540 creator A5013890164 @default.
• W2570112540 creator A5023752321 @default.
• W2570112540 creator A5052831034 @default.
• W2570112540 creator A5057911528 @default.
• W2570112540 creator A5071375525 @default.
• W2570112540 creator A5088292582 @default.
• W2570112540 creator A5028131599 @default.
• W2570112540 date "2009-11-20" @default.
• W2570112540 modified "2023-10-12" @default.
• W2570112540 title "Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results." @default.
• W2570112540 doi "https://doi.org/10.1182/blood.v114.22.3876.3876" @default.
• W2570112540 hasPublicationYear "2009" @default.
• W2570112540 type Work @default.
• W2570112540 sameAs 2570112540 @default.
• W2570112540 citedByCount "1" @default.
• W2570112540 countsByYear W25701125402012 @default.
• W2570112540 crossrefType "journal-article" @default.
• W2570112540 hasAuthorship W2570112540A5013047847 @default.
• W2570112540 hasAuthorship W2570112540A5013890164 @default.
• W2570112540 hasAuthorship W2570112540A5023752321 @default.
• W2570112540 hasAuthorship W2570112540A5028131599 @default.
• W2570112540 hasAuthorship W2570112540A5052831034 @default.
• W2570112540 hasAuthorship W2570112540A5057911528 @default.
• W2570112540 hasAuthorship W2570112540A5071375525 @default.
• W2570112540 hasAuthorship W2570112540A5088292582 @default.
• W2570112540 hasConcept C112705442 @default.
• W2570112540 hasConcept C126322002 @default.
• W2570112540 hasConcept C143998085 @default.
• W2570112540 hasConcept C2776364478 @default.
• W2570112540 hasConcept C2776694085 @default.
• W2570112540 hasConcept C2777478702 @default.
• W2570112540 hasConcept C2778367456 @default.
• W2570112540 hasConcept C2778822529 @default.
• W2570112540 hasConcept C2780401358 @default.
• W2570112540 hasConcept C535046627 @default.
• W2570112540 hasConcept C61943457 @default.
• W2570112540 hasConcept C71924100 @default.
• W2570112540 hasConcept C98274493 @default.
• W2570112540 hasConceptScore W2570112540C112705442 @default.
• W2570112540 hasConceptScore W2570112540C126322002 @default.
• W2570112540 hasConceptScore W2570112540C143998085 @default.
• W2570112540 hasConceptScore W2570112540C2776364478 @default.
• W2570112540 hasConceptScore W2570112540C2776694085 @default.
• W2570112540 hasConceptScore W2570112540C2777478702 @default.
• W2570112540 hasConceptScore W2570112540C2778367456 @default.
• W2570112540 hasConceptScore W2570112540C2778822529 @default.
• W2570112540 hasConceptScore W2570112540C2780401358 @default.
• W2570112540 hasConceptScore W2570112540C535046627 @default.
• W2570112540 hasConceptScore W2570112540C61943457 @default.
• W2570112540 hasConceptScore W2570112540C71924100 @default.
• W2570112540 hasConceptScore W2570112540C98274493 @default.
• W2570112540 hasIssue "22" @default.
• W2570112540 hasLocation W25701125401 @default.
• W2570112540 hasOpenAccess W2570112540 @default.
• W2570112540 hasPrimaryLocation W25701125401 @default.
• W2570112540 hasRelatedWork W1801735820 @default.
• W2570112540 hasRelatedWork W2056686464 @default.
• W2570112540 hasRelatedWork W2058808800 @default.
• W2570112540 hasRelatedWork W2072994817 @default.
• W2570112540 hasRelatedWork W2124042268 @default.
• W2570112540 hasRelatedWork W2570112540 @default.
• W2570112540 hasRelatedWork W2738602720 @default.
• W2570112540 hasRelatedWork W3105812043 @default.
• W2570112540 hasRelatedWork W4313857557 @default.
• W2570112540 hasRelatedWork W2504195627 @default.
• W2570112540 hasVolume "114" @default.
• W2570112540 isParatext "false" @default.
• W2570112540 isRetracted "false" @default.
• W2570112540 magId "2570112540" @default.
• W2570112540 workType "article" @default.